RMD ResMed Inc.

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

  • 36,000 people across 17 markets responded to the company’s fourth annual survey.

  • 40% of respondents get no more than three nights of good sleep per week.
  • More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality.



SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and other chronic diseases, today announced the results of its 2024 Global Sleep Survey in conjunction with World Sleep Day (March 15), shedding light on the critical sleep challenges faced by people around the world.

The survey uncovered a staggering number of people suffering from a chronic lack of good sleep, with nearly 40% of respondents getting no more than three nights of good sleep each week – and some individuals reporting just one. Respondents reported feeling excessive daytime sleepiness (50%), negative feelings in the morning (40%) and more irritable (39%).

In its fourth year, the survey is core to ResMed’s Discover Your Sleep Superpowers campaign and this year’s findings are even more comprehensive, with 36,000 participants across 17 markets providing insights on the state of sleep around the world.

A world in sleep crisis*

  • Across the surveyed population, only 13% of respondents reported sleeping well every night. People in Japan (57%) topped the list for the number of poor nights’ sleep each week while people in India were the most rested with 27% saying they sleep well every night.
  • Over half of our respondents used a digital device before going to bed, whether to scroll through social media (53%), watch TV (44%) or catch up on news (31%).
  • When asked about what was keeping them awake, the top reasons that emerged were personal anxiety (36%), insomnia (25%), breathing difficulties (15%), and obesity (13%).
  • Even after falling asleep, 3 in 10 respondents reported being unable to stay asleep without being woken up. People in the UK (44%) and France (42%) experienced the most disruption to their sleep while respondents from India (42%) and Thailand (41%) were most likely to fall and stay asleep the entire night.
  • Among female respondents who are perimenopausal or menopausal, 56% suffer from disturbed sleep, with women in Ireland and Australia being the most affected. In both countries, 3 in 4 women that are perimenopausal or menopausal said they suffer from disturbed sleep.



Discover your sleep superpowers

  • The top three benefits experienced by respondents after a night of good sleep were improved concentration (50%), increased productivity (51%) and improved mental health (44%).
  • Nearly 9 in 10 respondents also said that good sleep benefits them physically while 83% agree that good sleep enables them to be more creative.
  • People are also becoming more curious about how they sleep, with 36% of respondents tracking their sleep either through a smartphone app (44%) or wearable (31%).



“With sleep being the third pillar of health, alongside diet and exercise, prioritizing your sleep is one of the most effective ways to improve your overall health,” said Carlos, M. Nunez. M.D., ResMed Chief Medical Officer. “With over 936 million people around the world affected by sleep apnea1, it is concerning to learn that 40% of the people we surveyed get no more than three good nights of sleep a week. Poor sleep can be an indicator of conditions such as insomnia and sleep apnea, so this World Sleep Day we want to empower people to take charge of their sleep health and have conversations with their healthcare provider.”

Among survey respondents, 57% claim they are aware of sleep apnea, a chronic disease in which the muscles of the throat relax to the point of collapse, restricting airflow and causing the sufferer to stop breathing repeatedly throughout the night. Notably, however, only 26% of those respondents have been diagnosed.

To learn more about ResMed’s 2024 Global Sleep Survey or for help identifying if you have symptoms that could indicate poor sleep health, visit .

Survey Methodology

The 2024 ResMed Global Sleep Survey included a total of 36,000 respondents across 17 markets including Australia, Brazil, China, France, Germany, Hong Kong, India, Ireland, Japan, Korea, Mexico, New Zealand, Singapore, Taiwan, Thailand, UK and USA, between December 2023 and January 2024.

About ResMed

At ResMed we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

Contacts

For media                                                                                

+1 858.289.7272                                                        

                                                        

For investors

+1 858.836.5000

   



1 Benjafield A et al. Lancet Respir Med 2019)

*Based on 36,000 respondents across 17 markets surveyed as part of the ResMed 2024 Global Sleep Survey between December 2023 and January 2024



EN
15/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 202...

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024 Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2024. Third Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 7% to $1.2 billion; up 7% on a constant currency ba...

 PRESS RELEASE

ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024

ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024 SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  • Location: • Date:Thursday, April 25, 2024 • Time:1:30 p.m. PDT ...

 PRESS RELEASE

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis 36,000 people across 17 markets responded to the company’s fourth annual survey.40% of respondents get no more than three nights of good sleep per week.More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality. SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and othe...

 PRESS RELEASE

Introducing the AirFit F40: Experience Unprecedented Freedom with the ...

Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask.Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night. 96% of patients using the AirFit F40 said they have the freedom to sleep in their preferred positio...

ResMed Inc: 1 director

A director at ResMed Inc sold 23,535 shares at 182.664USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch